Pfizer: end of Phase III clinical study
(CercleFinance.com) - The US group Pfizer and the German Merck announced on Friday that they have decided to end phase III clinical trials to evaluate the effectiveness of their monoclonal antibody, avelumab, in the treatment of squamous cell carcinoma of the head and neck.
Both biopharmaceutical groups explain that they decided to comply with the recommendation of an independent committee, for which the tests are unlikely to show a significant improvement in patient survival without disease progression, the primary endpoint of the study.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
Both biopharmaceutical groups explain that they decided to comply with the recommendation of an independent committee, for which the tests are unlikely to show a significant improvement in patient survival without disease progression, the primary endpoint of the study.
Copyright (c) 2020 CercleFinance.com. All rights reserved.